Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 21INDUSTRY 21NIH 3NETWORK 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Central Nervous System Neoplasms 8Brain Neoplasms 5Astrocytoma 5Medulloblastoma 4Oligodendroglioma 3Glioma 3Glioblastoma 3Spinal Cord Neoplasms 1Optic Nerve Glioma 1Lymphoma, AIDS-Related 1Gliosarcoma 1Cognition Disorders 1

Interventions

Radiotherapy 15Temozolomide 14Carmustine 6Lomustine 3Chemotherapy, Adjuvant 3Bevacizumab 3imetelstat 2Radiosurgery 2Radiation 2Immunohistochemistry 2Everolimus 2DNA Methylation 2vistusertib 1veliparib 1vatalanib 1temsirolimus 1sagopilone 1rubitecan 1palbociclib 1mercaptoundecahydrododecaborate 1marizomib 1lonafarnib 1fluciclovine F-18 1carmustine, poliferprosan 20 drug combination 1beta-D-glucosylisophosphoramide mustard 1azurin (50-77) 1Tamoxifen 1Re-Irradiation 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Glioblastoma × Lomustine × Clear all
NCT05904119 2026-02-17

LEGATO

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
411 enrolled
CNS

Glioblastoma

NCT00100802 2023-02-15

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

Children's Oncology Group

Phase 2 Completed
118 enrolled 8 charts
CNSSarcoma

Astrocytoma, Glioblastoma, Spinal Cord Neoplasms, Central Nervous System Neoplasms, Gliosarcoma

NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡